Auph short interest.

Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in ...

Auph short interest. Things To Know About Auph short interest.

Historical equity short-Interest data for all listed tickers starting 2018 ... AUPH (Aurinia Pharmaceuticals Inc) Start Date:2013-11-08. AUR (Aurora Innovation ...Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value.In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...A short bio should include an introduction, information about education, relevant information regarding awards and achievements, and a conclusion. Depending on the purpose of the bio, it may also include relevant work experience and qualifi...AUPH 4.86%. Apple Inc. $191.24. AAPL 0.68%. Sarepta Therapeutics Inc. ... Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance ...

Shares of Aurinia Pharmaceuticals (AUPH) have gained 13.7% over the past four weeks to close the last trading session at $8.29, but there could still be a solid upside left in the stock if short ...WebAurinia Pharmaceuticals (NASDAQ: AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in ...

Overview of financial data and news for Aurinia Pharmaceuticals Inc., Nasdaq:AUPH

Aurinia Pharma (AUPH) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open.The consensus EPS Estimate is -$0.18 (+28.0% Y/Y) and the consensus...Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value.Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...Initially, Lupkynis seemed to be a promising treatment for LN, but its adoption has fallen short of expectations, as shown by Aurinia's failure to meet its 2022 revenue projections ($115-$135 ...

Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...

A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

The settlement with Sun Pharma appeared to spark some renewed speculation that the company could be a takeover target again. Dealreporter speculated at the time that Aurinia AUPH could be viewed as a takeout candidate with the patent overhang lifted. Aurinia AUPH short interest is 10.7%.Sep 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) named Dr. Robert Foster as a new board member Thursday as part of an agreement with its major shareholder and investment management firm, MKT Capital Ltd ... Auph only had 1 month of sales last quarter, due to insurance companys taking 20 to 50 days to approve each patient...thats the reason for sales short fall Reply Like (7) dToday's Open Interest: The total open interest for all option contracts (across all expiration dates). Open Int (30-Day) : The average total open interest for all option contracts …Aurinia Pharmaceuticals (NASDAQ: AUPH) has filed a $250M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. Shares are down 12% in ...

AUPH Short Interest Back to AUPH Overview NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on...Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...Global Coverage. Comprehensive ownership data of US Institutions, Mutual Funds, and ETFs targeting equities and bonds in mature, emerging, and frontier markets. Activist Investor 13D Filings. Beneficial Ownership 13G Filings. Institutional Ownership 13F Filings. Insider 3, 4 and 5 Filings.WebArrow Financial Co. (NASDAQ:AROW – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 153,000 shares, an increase of 13.1% from the February 28th total of 135,300 shares. Based on an average trading volume of 34,700 shares, the […]WebAUPH short interest is 12%. More on Aurinia. Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value; Aurinia Pharmaceuticals: All In On Lupkynis - A Tough Bet;AUPH / Aurinia Pharmaceuticals Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AUPH to the lender of that security. This fee is shown as an annual percentage rate (APR). M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interest

AUPH has a market cap of $1.3bn and a cash balance of $389mn. Research and development expenses were USD 9.9 million for 4Q. Selling, general and administrative expenses, inclusive of share-based ...Institutional Owners: 318 total, 304 long only, 0 short only, 14 long/short - change of 1.92% MRQ Average Portfolio Allocation: 0.0605 % - change of -12.95% MRQ

For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...Back to AUPH Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on …A typical short squeeze candidate has a high level of short interest, or percentage of outstanding float sold short. With the short side of the trade heavily crowded, and a few shares publicly ...Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals.Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals.Business, Economics, and Finance. GameStop Moderna Pfizer Johnson & Johnson AstraZeneca Walgreens Best Buy Novavax SpaceX Tesla. Crypto

The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value.

Aurinia Pharmaceuticals Ord. $ 7.29. AUPH (NASDAQ) -0.01. Short Squeeze Ranking™. view. Daily Short Sale Volume. view. Short Interest (Shares Short)

1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc.Dec 1, 2023 · The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an increase of 34.6% to the stock’s current value. Interest income was $4.5 million at September 30, 2023 versus $1.5 million for the prior year period. Interest income was $12.4 million and $2.2 million for the nine months ended September 30 ...2023-03-10 Short sale volume (not short interest) for $AUPH is 38%. http://shortvolumes.com/?t=AUPH $AEZS 37% $REGN 56% $XLV 46%. 11 Mar 2023 12:54:01WebAUPH has a market cap of $1.08bn and $400 million of cash, cash equivalents, restricted cash and investments as of October 31, 2022. In the previous quarter, the company made $55mn in revenue ...In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range ...It seems like the purpose of the document is to formalize the recent changes to the commercial partnership (originally announced here) as well as some of the items from the cooperation agreement released in February; particularly when it comes to the availability of stock warrants that Healios can execute once they achieve approvals for ARDS ... Sep 30, 2023 · Net amortization of premiums and discounts on short-term investments (8,836) (14) Share-based compensation expense: 33,543 25,398 Write-down of inventory: 916 2,464 Other, net (3,910) 601 Net changes in operating assets and liabilities: Accounts receivable, net (24,463) (26,356) Inventories, net (8,984) (8,458) Prepaid expenses and other ... Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at data ...Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.

AUPH / Aurinia Pharmaceuticals Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AUPH to the lender of that security. This fee is shown as an annual percentage rate (APR). Zhanna Hapanovich/iStock via Getty Images. Aurinia Pharmaceuticals (NASDAQ: AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers ...Jun 29, 2023 · Aurinia Pharmaceuticals (AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. ... Also, with 11%+ short interest, there should be some "motivated ... The Quality+Value Score was analysed by an independent firm and they found that an investing strategy based on the model outperformed both the Russell 2000 and the S&P over time. In one test over the period of 1992 to 2013, the theoretical CAGR of the Quality+Value score was 20.73% vs. the Russell 2000 CAGR of 10.33%.Instagram:https://instagram. learn to trade onlineetfs for roth irastocks for ainvda ex dividend AUPH | Aurinia Pharmaceuticals short interest and earnings date annual report Jul, 2023 Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8. Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272. SIC: 2834 - PHARMACEUTICAL PREPARATIONS. State location: A1 | State of Inc.: A0 | …Cantor Fitzgerald Reiterates Aurinia Pharmaceuticals (AUPH) Overweight Recommendation. ... Highest Short Float; Owners Retail Ownership Most Popular Funds Activist Investors Fund Sentiment - World. United States Canada UK Hong Kong Japan Australia New Zealand. adobt stocktop semiconductor stocks Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling ... vanguard blv Aptevo Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 26,900 shares, a decline of 74.2% from the October 31st total of 104,300 shares. Based on an average daily volume of 483,200 shares, the short-interest ratio is currently 0.1 days. View Aptevo Therapeutics' Short …Dec 2, 2021 · Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). Novartis reportedly said during its R&D day earlier...